HomeAI · summaries
Storia in 3 fonti
Diabetic macular edema eye drop from Oculis fails to meet primary endpoint
Oculis will not pursue FDA approval for OCS-01, an eye drop for diabetic macular edema, after it failed to meet the primary endpoint in a phase 3 program, according to a press release.The DIAMOND program included two phase 3 trials that evaluated OCS-01 (dexamethasone 15 mg/mL) in more than 800 patients with DME. Both trials, DIAMOND-1 and DIAMOND-2, failed to meet their primary endpoint of mean
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
endpoints.news
Oculis’ eye drops for diabetic macular edema flunk Phase 3 test
Oculis saw its stock plummet after reporting that its investigational eye drops for diabetic macular edema (DME) did not succeed in a pair of Phase 3 trials.
- ·
benzinga.com
Why Is Oculis Stock Sinking Monday? - Oculis Holding (NASDAQ:OCS)
Oculis (OCS) stock plummets 37% after its Phase 3 DIAMOND trials for diabetic macular edema fail to meet the primary endpoint.
